Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

662149.pdf (809.08 KB)

Document type

Article

Version

Accepted version

Publication date

2016-04-30

Publication license

cc-by-nc-nd (c) Elsevier B.V., 2016
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/129363

PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen in vitro, ex vivo and in vivo characterization

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.colsurfb.2016.04.054

Abstract

Dexibuprofen-loaded PEGylated PLGA nanospheres have been developed to improve the biopharmaceuti-cal profile of the anti-inflammatory drug for ocular administration. Dexibuprofen is the active enantiomerof ibuprofen and therefore lower doses may be applied to achieve the same therapeutic level. Accordingto this, two batches of nanospheres of different drug concentrations, 0.5 and 1.0 mg/ml respectively, havebeen developed (the latter corresponding to the therapeutic ibuprofen concentration for inflammatoryeye diseases). Both batches were composed of negatively charged nanospheres (-−14.1 and -−15.9 mV),with a mean particle size below 200 nm, and a high encapsulation efficiency (99%). X-ray, FTIR, and DSCanalyses confirmed that the drug was dispersed inside the matrix of the nanospheres. While the in vitrorelease profile was sustained up to 12 h, the ex vivo corneal and scleral permeation profile demonstratedhigher drug retention and permeation in the corneal tissue rather than in the sclera. These results werealso confirmed by the quantification of dexibuprofen in ocular tissues after the in vivo administration ofdrug-loaded nanospheres. Cell viability studies confirmed that PEGylated-PLGA nanospheres were lesscytotoxic than free dexibuprofen in the majority of the tested concentrations. Ocular in vitro (HET-CAMtest) and in vivo (Draize test) tolerance assays demonstrated the non-irritant character of both nanospherebatches. In vivo anti-inflammatory effects were evaluated in albino rabbits before and after inflammationinduction. Both batches confirmed to be effective to treat and prevent ocular inflammation. Keywords: Nanospheres, Dexibuprofen, PLGA, PEG, Inflammation, Drug delivery

Subject

Nanopartícules, Farmacologia experimental, Sistemes d'alliberament de medicaments, Inflamació

Subject (English)

Nanoparticles, Experimental pharmacology, Drug delivery systems, Inflammation

Citation

Collections

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Citation

SÁNCHEZ-LÓPEZ, E. (Elena), et al. PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen in vitro, ex vivo and in vivo characterization. Colloids and Surfaces B-Biointerfaces. 2016. Vol. 145, num. 241-250. ISSN 0927-7765. [consulted: 17 of August of 2026]. Available at: https://hdl.handle.net/2445/129363

Export metadata

JSON - METS

Share record